In Brief

EWG slams FDA sunscreen oversight; NARB stays the course in Healthy Directions case; AHPA presses FDA on NDI ID guidance; CRN comments on “chemically altered” NDIs; and Desert Rose products lack full labels.

The U.S. market still lags behind Europe when it comes to safe and effective sunscreen products, the Environmental Working Group maintains in its annual Sunscreen Guide rating more than 1,400 products. Summer 2013 is the first summer after manufacturers were required to comply with an FDA rule requiring sunscreen products to feature an SPF 15 or higher and meet criteria for broad-spectrum protection to claim they reduce the risk of skin cancer or early skin aging caused by sun exposure Also see "FDA Strengthens Sunscreen Testing And Label Requirements" - Pink Sheet, 20 June, 2011.. EWG maintains FDA’s standards are not high enough. Just 25% of sunscreen products reviewed passed muster with the group, which cited products for containing oxybenzone and/or retinyl palmitate, both linked to adverse health effects. EWG also takes issue with sunscreen sprays and products with SPFs above 50. FDA released a proposed rule in June 2011 to cap sunscreens at 50+, as well as an advanced notice of proposed rulemaking asking firms to submit safety and efficacy data for spray sunscreens, lest they be excluded from the final monograph (Also see "FDA Considers Capping SPF Values At 50+ Despite Efficacy Data" - Pink Sheet, 20 June, 2011. and Also see "FDA Questions Spray Sunscreen Safety, Efficacy And Monograph Status" - Pink Sheet, 27 June, 2011.).

The National Advertising Review Board recommends Healthy Directions LLC discontinue several claims for Joint Advantage Gold, including that thesupplement product’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

Lawyers Weigh In On ‘Sunshine’ Clause In EU Pharma Reform Package

 

The Council of the EU has not taken forward a proposal from the European Parliament that would require companies to disclose the transfers of value they make to health care professionals and health care organizations – lawyers weigh in on the diverging proposals.

EU Pharma Overhaul May Reshape Aspects Of Drug Promotion And HCP Partnerships

 

Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”

‘Sex Pill For Women’: Sprout CEO’s Addyi Instagram Post Draws US FDA Warning Letter

 
• By 

Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By 

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.

More from Compliance

ICH Proposes Global Framework For Managing Leachables In Pharma Products

 
• By 

The International Council for Harmonisation has developed a holistic approach for the assessment and control of leachable impurities, supporting drug product development, registration and ongoing quality management throughout the product lifecycle.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By 

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making the forecasting environment for the pharma industry extremely difficult, the Pink Sheet finds in this infographic analysis.

Manufacturers Can Keep Their Shoes On: FDA PreCheck To Streamline US Facility Applications

 

The program would allow early interactions with FDA staff to speed construction and approval of pharmaceutical manufacturing facilities in the US, but will staff be available?